Cargando…
New insights into CAR T cell-mediated killing of tumor cells
Adoptive transfer of T cells genetically engineered to express chimeric antigen receptors (CAR) has demonstrated striking efficacy for the treatment of several hematological malignancies, including B-cell lymphoma, leukemia, and multiple myeloma. However, CAR T-cell efficacy has been very limited in...
Autores principales: | Espie, David, Donnadieu, Emmanuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521365/ https://www.ncbi.nlm.nih.gov/pubmed/36189315 http://dx.doi.org/10.3389/fimmu.2022.1016208 |
Ejemplares similares
-
Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors
por: Donnadieu, Emmanuel, et al.
Publicado: (2020) -
CAR-NK Cells: From Natural Basis to Design for Kill
por: Khawar, Muhammad Babar, et al.
Publicado: (2021) -
Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing
por: Ingegnere, Tiziano, et al.
Publicado: (2019) -
Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line
por: Wang, Lingyan, et al.
Publicado: (2022) -
CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)